BONACA, Marc P., Shinya GOTO, Deepak L. BHATT, P. Gabriel STEG, Robert F. STOREY, Marc COHEN, Erica GOODRICH, Laura MAURI, Ton Oude OPHUIS, Mikhail RUDA, Jindřich ŠPINAR, Ki-Bae SEUNG, Dayi HU, Anthony J. DALBY, Eva JENSEN, Peter HELD, David A. MORROW, Eugene BRAUNWALD a Marc S. SABATINE. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation. Philadelphia: Lippincott Williams and Wilkins, 2016, roč. 134, č. 12, s. "861"-"+", 21 s. ISSN 0009-7322. Dostupné z: https://dx.doi.org/10.1161/CIRCULATIONAHA.116.024637.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54)
Autoři BONACA, Marc P. (840 Spojené státy), Shinya GOTO (392 Japonsko), Deepak L. BHATT (840 Spojené státy), P. Gabriel STEG (826 Velká Británie a Severní Irsko), Robert F. STOREY (826 Velká Británie a Severní Irsko), Marc COHEN (840 Spojené státy), Erica GOODRICH (840 Spojené státy), Laura MAURI (840 Spojené státy), Ton Oude OPHUIS (528 Nizozemské království), Mikhail RUDA (643 Rusko), Jindřich ŠPINAR (203 Česká republika, garant, domácí), Ki-Bae SEUNG (410 Korejská republika), Dayi HU (156 Čína), Anthony J. DALBY (710 Jižní Afrika), Eva JENSEN (752 Švédsko), Peter HELD (752 Švédsko), David A. MORROW (840 Spojené státy), Eugene BRAUNWALD (840 Spojené státy) a Marc S. SABATINE (840 Spojené státy).
Vydání Circulation, Philadelphia, Lippincott Williams and Wilkins, 2016, 0009-7322.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 19.309
Kód RIV RIV/00216224:14110/16:00092730
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024637
UT WoS 000384059400009
Klíčová slova anglicky hemorrhagic stroke; ischemic stroke; platelet aggregation inhibitors; secondary prevention; stroke; thrombosis; ticagrelor
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 12. 4. 2018 16:57.
Anotace
BACKGROUND: In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention. We investigated the incidence of stroke, outcomes after stroke, and the efficacy of ticagrelor focusing on the approved 60 mg twice daily dose for reducing stroke in this population. METHODS: Patients were followed for a median of 33 months. Stroke events were adjudicated by a central committee. Data from similar trials were combined using meta-analysis. RESULTS: Of 14 112 patients randomly assigned to placebo or ticagrelor 60 mg, 213 experienced a stroke; 85% of these strokes were ischemic. A total of 18% of strokes were fatal and another 15% led to either moderate or severe disability at 30 days. Ticagrelor significantly reduced the risk of stroke (hazard ratio, 0.75; 95% confidence interval, 0.57-0.98; P=0.034), driven by a reduction in ischemic stroke (hazard ratio, 0.76; 95% confidence interval, 0.56-1.02). Hemorrhagic stroke occurred in 9 patients on placebo and 8 patients on ticagrelor. A meta-analysis across 4 placebo-controlled trials of more intensive antiplatelet therapy in 44 816 patients with coronary disease confirmed a marked reduction in ischemic stroke (hazard ratio, 0.66; 95% confidence interval, 0.54-0.81; P=0.0001). CONCLUSIONS: High-risk patients with prior myocardial infarction are at risk for stroke, approximately one-third of which are fatal or lead to moderate-to-severe disability. The addition of ticagrelor 60 mg twice daily significantly reduced this risk without an excess of hemorrhagic stroke but with more major bleeding. In high-risk patients with coronary disease, more intensive antiplatelet therapy should be considered not only to reduce the risk of coronary events, but also of stroke.
VytisknoutZobrazeno: 19. 9. 2024 04:29